戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e binding site on tubulin differing from the vinca alkaloid and dolastatin 10 binding sites, or that
2  the shortest (five-step) total synthesis of vinca alkaloid catharanthine to date, proceeding via its
3     The ability of a class of C-20' modified vinca alkaloid congeners to induce tubulin spiral format
4 e studies comparing the interaction of a new vinca alkaloid derivative, vinorelbine (Navelbine), with
5 ategy has allowed fast access to a family of vinca alkaloid derivatives with an enlarged and function
6 tafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH),
7 or the response of breast cancer patients to Vinca alkaloid drug treatment.
8  Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it co
9 e role of single-agent vinblastine and other vinca alkaloid in the management of pediatric LGGs deser
10                        Vinflunine is a novel Vinca alkaloid presently in Phase I clinical trials.
11 ults indicate that cryptophycin disrupts the Vinca alkaloid site of tubulin; however, the molecular d
12          Since chemical modifications of the vinca alkaloid structure are known to modulate the overa
13 lls created by continuous selection with the vinca alkaloid vincristine (HL60 RV+) or by retroviral i
14 hat vinpocetine, a synthetic derivative of a vinca alkaloid, and hardwickiic acid, a natural product
15 ubulin that is distinct from the colchicine, vinca alkaloid, and paclitaxel binding sites and some, i
16 ne (Navelbine), an amphiphilic semisynthetic Vinca alkaloid, has displayed superior activity and decr
17                          Vinflunine, a novel vinca alkaloid, showed some activity and was recently ap
18 ffer significantly from those of the classic Vinca alkaloid, vinblastine.
19 itors sodium azide/2-deoxyglucose and by the vinca alkaloid, vincristine, but not by the chemotherape
20 ntered by cancer patients receiving taxane-, vinca alkaloid- or platin-based chemotherapy.
21  nucleotides are allosteric effectors of the vinca alkaloid-induced self-association of tubulin.
22 ed by the observation that the energetics of vinca alkaloid-induced tubulin spiral polymers, or spira
23 erently from vinblastine, a first generation Vinca alkaloid.
24 kg, intravenous methylprednisolone 30 mg/kg, Vinca alkaloids (VCR 0.03 mg/kg), and/or intravenous ant
25 o other groups of anticancer drugs including vinca alkaloids (vinblastine and vincristine) and anthra
26  the massive stable structures observed with vinca alkaloids and antimitotic peptides.
27 with Dx5, with decreased cross-resistance to Vinca alkaloids and no resistance to dactinomycin.
28 ive inhibition of the tubulin binding of the Vinca alkaloids and other antimitotic agents, (2) proxim
29                                   Hybrids of vinca alkaloids and phomopsin A have been elaborated wit
30 ent antimitotic cancer chemotherapy based on vinca alkaloids and taxanes target tubulin, a protein re
31                   Some of the drugs, such as Vinca alkaloids and taxol, are routinely used for cancer
32                                              Vinca alkaloids appear to inhibit cell proliferation by
33                                  Taxanes and Vinca alkaloids are among the most active classes of dru
34                                              Vinca alkaloids are antimitotic drugs that inhibit micro
35                                              Vinca alkaloids are antineoplastic agents that halt cell
36                                  Taxanes and vinca alkaloids are in widespread use and have demonstra
37  residues that are crucial to the binding of vinca alkaloids are shown to be strongly involved in lon
38  of the initial interaction between P-gp and Vinca alkaloids occurs in the cytoplasm.
39                    Drugs such as taxanes and vinca alkaloids specifically target microtubules and cau
40 hmin expression on the action of taxanes and Vinca alkaloids using a panel of human breast cancer cel
41 ty (many-fold greater than paclitaxel or the vinca alkaloids) raises important questions about its me
42 otherapeutic drugs (e.g., anthracyclines and vinca alkaloids) should concentrate in acidic organelles
43 775), KSP (ispinesib), and tubulin (taxanes, vinca alkaloids), are presented.
44 nclude liposomal anthracyclines, paclitaxel, vinca alkaloids, and bleomycin.
45 ance to anthracyclines, epipodophyllotoxins, vinca alkaloids, and some alkylating agents.
46 e to killing by MDR-sensitive drugs, such as vinca alkaloids, anthracyclines, podophyllins, and pacli
47 geting agents (MTA), such as the taxanes and vinca alkaloids, are used to treat a variety of cancers
48                       AB-5, like taxanes and vinca alkaloids, blocks cell division during mitosis.
49 often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including a
50  agents in clinical use, the taxanes and the vinca alkaloids, come from terrestrial sources, the sea
51 ide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect
52 active route to the tetracyclic core of some vinca alkaloids, including the tetrahydroisoquinocarbazo
53             Cross-resistance was observed to Vinca alkaloids, including vincristine, vinorelbine, and
54 superior antitumor activity to that of other Vinca alkaloids, including vinorelbine from which it was
55            Whereas many drugs, including the vinca alkaloids, often become less effective when p53 is
56 y developed a new group of folate-conjugated Vinca alkaloids, one of which, EC145, emerged as a candi
57 xic agents such as liposomal anthracyclines, vinca alkaloids, or paclitaxel.
58 ored cellular sensitivity to anthracyclines, Vinca alkaloids, taxanes, and other anticancer drugs.
59 ly with platinum- and taxane-based regimens, vinca alkaloids, thalidomide and bortezomib, and is also
60                    The two second-generation Vinca alkaloids, vinorelbine and vinflunine, affect micr
61 eases microtubule binding and sensitivity to Vinca alkaloids, which promotes microtubule depolymeriza
62 grafted tumors as effectively as taxanes and vinca alkaloids.
63 rarely has been applied to studies involving vinca alkaloids.
64 umor activities of the two second-generation Vinca alkaloids.
65 e efficacy of paclitaxel, docetaxel, and the vinca alkaloids.
66 , including platinum compounds, taxanes, and vinca alkaloids.
67 nding of paclitaxel and increased binding of Vinca alkaloids.
68 y to paclitaxel and decreased sensitivity to vinca alkaloids.
69 s using anthracyclines, glucocorticoids, and Vinca alkaloids.
70 r 6 mutants were cross-resistant only to the Vinca alkaloids.
71 ivative, vinorelbine (Navelbine), with other vinca alkaloids.
72 f the energetics of spiral formation for two vinca alkaloids: a novel difluorinated vinorelbine deriv
73 ncer treatment including taxanes, platinums, vinca-alkaloids, proteasome inhibitors, and thalidomide.
74 e zoospores of P. nicotianae infected annual vinca and P. sojae race 25 successfully attacked a non-h
75 he total synthesis of several members of the vinca and tacaman classes of indole alkaloids has been a
76 s resistant to other antimicrotubule agents, vincas and taxanes, were screened.
77                       The ADC prepared had a vinca-antibody ratio of 20:1.
78 e dilantin binding site is distinct from the Vinca binding site, and these independent binding modes
79 gion of the tubulin heterodimer close to the vinca binding site.
80 ielded a distance between the colchicine and vinca binding sites on tubulin of approximately 40 A.
81            Further studies reveal that these VinCAs can serve as effective cell imaging agents, showc
82  Gossypium hirsutum) and ornamental species (vinca, Catharanthus roseus).
83                         The first example of vinca derivatives 16-18 able to modulate P-glycoprotein
84 ing studies, carried out with two of the new vinca derivatives, provide useful hints about how a give
85 te on beta-tubulin that is distinct from the vinca domain and that blocks the formation of longitudin
86 e "vinca site" and the "peptide site" of the vinca domain in tubulin.
87 and bacterial peptide-like inhibitors of the vinca domain, sharing a very similar binding mode with t
88 tion of alpha beta-tubulin dimers with three vinca domain-binding peptides--cryptophycin 1, hemiaster
89                      Using trastuzumab and a vinca drug derivative to demonstrate the utility of this
90 gs in clinic today, particularly taxanes and Vincas, face challenges including frequent visits to the
91                     We demonstrate here that vinca-induced tubulin-spiraling potential is significant
92 diverse peptide-like molecules, binds to the Vinca-peptide site in tubulin, disrupts normal microtubu
93                Four previously unidentified, Vinca-related mutations, involving three amino acids, ha
94 orated with the aim of interfering with the "vinca site" and the "peptide site" of the vinca domain i
95 heterodimers (i.e., the seventh site and the vinca site).
96 5-loop site" that bridges the maytansine and vinca sites.
97 taxel.1 Instead, they inhibit the binding of vincas to tubulin.
98 r-acceptor-type Vinylogous Cyano Aminoaryls (VinCAs) with diverse emission colors.